A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 16 Dec 2017
At a glance
- Drugs MAK 683 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Nasopharyngeal cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 14 Mar 2017 Planned primary completion date changed from 5 Aug 2019 to 8 Feb 2018.
- 22 Nov 2016 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
- 22 Nov 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2019.